Clinical Trial Update: Study of AFP464 +/- Faslodex in ER + Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of AFP464 with or without Faslodex in ER-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AFP464
• Faslodex (fulvestrant)

Snippet

Sponsor: Tigris Pharmaceuticals | Conditions: Breast Neoplasm | Phase 2 | Status: TERMINATED